ࡱ> zat2d)`&NȔ( ( / 0DTimes New Romanttқ 0DArialNew Romanttқ 0" DWingdingsRomanttқ 00DTahomagsRomanttқ 0"@DGill Sans MTanttқ 0"PDSymbolns MTanttқ 0`DArial Blackanttқ 0"@ .  @n?" dd@  @@`` z` +S  Q<  >6= $>x9T     G   ( - GGGG>I  >< $\      I$ Q< C6< $=<<<y9S  (+        $#   MB  J U     = 6H  99EG LP QRSTV #] c deghlmotuv#wx%yz {'   )># !+ (((   %# 7      ,r$t2d)`&NȔi AA1? ff333f3@42d2d  0ppppU pp ,:ʚ;ģ8ʚ;<4!d!d@ x 0@<4dddd@ x 0@<4dddd@ x 0@pDg4OdOdlu 0Xp po0___PPT10 pp`___PPT9B/ 0&? 5O =_3ADVANCES IN THE HORMONAL TREATMENT OF BREAST CANCER4&TURKISH-HELENIC ESMO COURSE 1-4 DECEMBER 2005- iSTANBUL P1nar Saip University of 0stanbul, Institute of Oncology Department of Medical Oncology $PFN3Advances in the Hormonal Treatment of Breast Cancer4fProper selection of endocrine responsive disease Adjuvant endocrine therapy for early stage breast cancer premenapausal postmenapausal Neoadjuvant endocrine therapy in post menapausal women Endocrine treatment for advanced disease premenapausal postmenapausal 6kMbMgg91Proper selection of endocrine responsive disease 2$Who are really endocrine responsive?%^HR  positive disease is heterogeneous disease0A subset of HR+ patients can expect a relatively large benefit with CT, another group of patients may obtain little or no benefit Not all HR+ disease responds to endocrine therapy Consentration of HR varies among breast carcinomas Increased concentration of steroid hormone receptors is associated with increased effectiveness of endocrine therapies mortality reduction with TMX 23% for low consentration 36% for high consentration *c-`HR  positive disease is heterogeneous disease 1 Presence of PR improves the benefit from adjuvant TAM treatment ATAC (anastrozol vs tamoxifen) ER+, PR+ HR: 0.82 ER+, PR- HR: 0.48 (e84There is an inverse relationship between PR and HER254 HER 2 + ER+ PR+ 8.2% ER+ PR- 29.5% This inverse relationship may in part be explained by PR levels in breast cancer cells being down regulated by the growth factors VQZZ.ZZ/ZZ550!Relationship between ER and HER 2" At presentation ER+ , HER2 - 70% ER+, HER2 + 10% ER-, HER2 + 10% ER-, HER2 - 10% In HER 2+ population the proportions of ER+ and ER- tumor are about equal The level of ER is lower in ER+ HER2+ cases than in ER+ HER2- . The biology and clinical behavior of ER+ HER2+ tumors may in part be explained by their lower ER expression $PP3$Prediction of response to tamoxifen %RThere is tamoxifen resistance in ER+, HER2+ tumors Ovarian Ablation +TAM is more effective in premenapausal patients Aromatase inhibitors are more effective in postmenapausal women response rate (HER2+) letrozole %88 TAM %213 SS;tA Multigene assay to predict recurrence of tamoxifene treated, nod (-) breast cancer Paik et al NEJM 2004;351: 2817uuuTo determine whether the results of RT-PCR of prospectively selected genes (16) would correlate with distant recurrence and response to Tam . (NSABP-B14) A mathematical algorithm RS was developed based on expression levels of these genes Patients categorised as low, intermediate and high risk according to their RT-PCR profiles Kaplan Meier estimates of the rate of distant recurrence at 10 years according to RS risk categories Risk category percentage of patients rate of distant recurrence Low 51 6.8 (4.0-9.6) Intermediate 22 14.3(8.3-20.3) High 27 30.5(23.6-37.4) The rate in the low risk group was significantly lower than the high risk group <0.001TIP_PIW5xMultivariate Cox analysisVariable p value HR(95%CI) without RS Age at surgery 0.004 0.57(0.39-0.83) Clinical tumor size 0.06 1.44(0.99-2.11) With RS Age at surgery 0.08 0.71(0.48-1.05) Tm size 0.23 1.26 (0.86-1.86) Recurrence score <0.001 3.21 (2.23-4.61) FA .rPaik et al ASCO 2005 DFS at 10 years Benefit of TAM placebo TAM absolute relative p % % % % Low 85.9 93.1 7.2 51% .04 Intermediate 62.2 79.5 17.3 46 .02 High 68.7 70.3 1.6 5 .82  ;5 ST GALLEN CONSENSUS MEETING 2005!{ RATHER THAN THE EARLIER RISK ASSESSMENT APPROACH, ENDOCRINE RESPONSIVENESS OF THE DISEASE BECAME THE MAIN CONSIDERATION.|62005 St Gallen 474FEATURES OF UNCERTAINITY TO ENDOCRINE RESPONSIVENESS5LOW LEVELS OF STEROID HORMON RECEPTORS LACK OF PROGESTERONE RECEPTORS OVEREXPRESSED OR AMPLIFIED HER2 HIGH NUMBER OF LYMPH NODES HIGH TUMOR LEVELS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR INCREASED PROLIFERATION MARKERS V) ADVANCES IN ADJUVANT ENDOCRINE THERAPY *eSystemic adjuvant endocrine treatment for early breast cancer significantly reduces recurrence and mortality 15 years after treatment(EBCTCG) meta-analysis 194 randomised trials up to 1995- 144,939 women trials n death Tamoxifen 1-2 yrs vs none 44 33.209 13914 5 yrs vs none 12 15017 4071 Ovarian A/S Ablation vs none 15 6506 3006 Suppresion vs none 6 4807 832 1tReduction after 15 years; breast ca p mortality p recurrence Tamoxifen 5 yrs 11.8 <.00001 9.2 <.00001 vs none, ER+ Ovarian A/S vs 4.3 .0001 3.2 .004 none<<<T   GOvarian supression/ablation Alone as an Alternative to Chemotherapy: "HG$*ZEBRA ( J Cancer 2003;39:1711) IBCSG VIII (J Nat C Inst 2003;95:1833) Scottish (Breast 2002;11:419) TABLE (Anticancer Res 2002;22:2325) !OA/OS alone vs Chemotherapy (CMF)""!  !OA/OS + Tamoxifen vs chemotherapy"?ABCSG Jakesz JCO 2002;20:4621 GROCTA Boccardo JCO 2000;18:2718 @ ;Ovarian ablation/supression + Tamoxifen vs chemotherapy (1)<<;  "*Chemotherapy vs CT OA TAM+$ ($ INT 0101 Davidson Proc ASCO; 2003; 22:15 France Arriagada Proc ASCO 2003;22:4 Mam-1 GOCSI Bianco Proc ASCO 2001;20,20 IBCSG 11-93 IBCSG The Breast 2001;10:130 5 Ovarian ablation/supression after chemotherapy (2)66"( `Study Treatment Disease characteristics Result in terms of OS France CT (any) Nod+/- No difference CT (any) +OA(RT/ medical Mam-1 CMF Node+, ER +/- G+Tam>CT GOCSI A CMF p=0.04 (n=466) CMF G+ Tam (2Y) A CMF G+ Tam (2Y) IBCGS AC X 4 +OA(G,S,RT)+Tam(5Y) Nod+, ER+ No difference 11-93 OA (G, S, RT) + Tam (5Y) INT-0101 CAF Nod +, ER+ CAF + G = CAF N: 1504 CAF + G (5 Y) CAF + G + Tam > CAF +G CAF+G +Tam p<0.01 dfs l " dP " !  'H "  Conclusions "Ovarian function supression plus tamoxifen is at least as effective as chemotherapy The current contravery remains in patients who continue to menstruate after CT whether the additon of OS improves the results compared to tam alone The role of AI in premenapausal women is not known yet. #:Questions in the onging trials SOFT: PERCHE TEXT M$Endocrine responsive St Gallen 2005 %Risk Premenapausal Postmenapausal Low risk Tam or Nil Tam or AI or Nil or OFS Intermediate Tam (OFS) (CT),or Tam or CT Tam (OFS),or AI,or Tam alone,or CT Tam or OFS CT AI High CT Tam or CT Tam or CT Tam+ OFS,or CT AI CT (AI + OFS) 2Z"\  I N-Endocrine response uncertain St Gallen 2005 .Risk Premenapausal Postmenapausal Low risk Tam or Nil Tam or AI or Nil or GnRHA Intermediate CT Tam (OFS),or CT AI,or Tam OFS (CT),or CT Tam CT AI +OFS OFS Switch High CT Tam or CT AI or CT Tam+ OFS,or CT Tam CT (AI + OFS) SwitchLPPPPP\ D  fCAdvances in the adjuvant hormonal treatment of postmenapausal womenDZUpfront Aromatase inhibitors Switching aromatase inhibitors Extended aromatase inhibitors[!Results of the ATAC trial after 5 years adjuvant treatment -Upfront AI $KIB*  ,#( Disease-free survival (ITT* population)")$($ ) %!Overall survival (ITT population)""$ " 4Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,224 women enrolled in the ABCSG Trial 8 and the ARNO 95 trialjAustrian Breast & Colorectal Cancer Study Group (ABCSG) and the German Adjuvant Breast Cancer Group (GABG)kPk6Switching trial ABCSG 8  ARNO 95: Combined analysis trial structureE#"58Event-free survival [oIntergroup exemestane study-IES: 50% nod-, 80%HR+, n:4742 median follow up 30.6 months swithcing trial "p$Lp\:Intergroup exemestane study ";9;'/Extended AI trial letrozol vs placebo -MA 174  (8MA.17 Results: Disease-Free Survival (Primary End Point)99 9 )MA.17 Results: Overall Survival **MA.17 Results: Subanalysis of Nodal Status&    1Letrozole is effective regardless of nodal status22 2 DABest ajuvant endocrine treatment strategy in postmenapausal womenB#lUnanswered QuestionsWhat is the best strategy? How long should we use? Will the AI-associated benefit long lasting? In which patients should we use (erbB1/2+, NOD+, PR- )?? Is it beneficial in premenapausal women with LHRHa Will it translate into a long term survival gain? Z$mOngoing trials  5 year TMX 5 year Letrozol 2-3 y letrozol + 2-3 y TMX 2-3 y TMX + 2-3y Letrozol 5 y1l TMX + 5 y1l plasebo 5 y1l TMX + 5 y EXE 5 y TMX 5 y EXE P J z3 'pASCO Technology assessment on the use of AIs as adjuvant therapy for postmenapausal women with HR+ breast cancer: Status report 2004tOnly one trial MA17 showed survival benefit in node positive patients The others show a clear and consistent improvement in disease free survival. Panel believes that optimal adjuvant hormonal treament for a postmenapausal women with HR+ disease should include an AI either as initial therapy or after treament withTAM. Risks and benefits of AIs should be considered uuuY Advances  %In the neoadjuvant hormonal treatment&ZNeoadjuvant phase III trialsDP024:Response rates and HER &  ~ letrozole Tamoxifen p HER + 15/17 4/19 0.0004 ER + (88%) (21%) HER - 55/101 42/100 0.0780 ER + (54%) (42%) !A0`.`d      (* (h"Advances in the hormonal treatment#Advanced Disease)ijLHRH Agonist + Tamoxifen in Pre-/perimenopausal Women with Advanced Breast Cancer: An EORTC Meta-analysis kTThe combination of LHRH agonist + tamoxifen is superior to LHRH agonist alone in the treatment of advanced breast cancer in hormone-sensitive pre-/perimenopausal women @P*j__Fulvestrant vs anastrozole after first line TAM US and rest , Randomized, Double-blind 2 trialsB/ a.Fulvestrant vs anastrozole Time to Progressionk.Fulvestrant vs anastrozole Time to Progression3vFulvestrant vs TAM first line Median follow up 14.5 TTP 6.8 (FUL) 8.3 (TAM) HR+ patients TTP 8.2 and 8.3 month RR 31.6% and 33.9% NO DIFFERENCE JCO 2004; 22,16054A 8Endocrine therapy in Advanced Breast Cancer: Conclusions'FThe efficacy of LHRH agonists in advanced disease is enhanced by the addition of tamoxifen in premenapausal women Aromatase inhibitors are the first line endocrine treatment option in postmenapausal women. Fulvestrant is active in tamoxifen resistant disease and at least as effective as AIs and offers a new alternative. 0F@PZAPZF(Q P Thank you for your consentration/L*+;<=vw|     +   0` ̙33` ` ff3333f` 333MMM` f` f` 3>?" dd@?lKd(@ u( " d@ ` n?" ddx@ h @@``PR    @ ` ` p>> L0 t(    T gֳgֳ ?  T Click to edit Master title style! !:  T(ygֳgֳ ?Pp  RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S  Tgֳgֳ ?``  ^*   T>gֳgֳ ?`   `*   T6gֳgֳ ?`   `* Z  B޽h @? ? f33 Default Designb 0 r(    Tr|r| ?O3  3 x*  R))RR{{  Tr|r| ? 3 3 z*  R))RR{{j  s *1 ?rm  3H  Tr|r| ?"`e @1 3 RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S  Zr|r| ?O   x*  R))RR{{  Zr|r| ?   z*  R))RR{{H  0whg? ? ̙3380___PPT10.Ќ   (     Tj r|r| ?O3   x*  R))RR{{  T r|r| ? 3   z*  R))RR{{  Z̤ r|r| ?O    x*  R))RR{{  Z r|r| ?    z*  R))RR{{H  0whg? ? ̙3380___PPT10.pބ< 0 L0 P $(   r  S >  r  S 4 `    H  0޽h ? f3380___PPT10.x <  0 L0 p $(   r  S     r  S ۛ  H  0޽h ? f3380___PPT10.=xW< 0 L0 0 $(  0 r 0 S 辛>  r 0 S g `    H 0 0޽h ? f3380___PPT10. H  0 L0 l 0(  l x l c $H.   x l c $؛p  H l 0޽h ? f3380___PPT10.``IH  0 L0  0(   x  c $4l   x  c $ЂPp  H  0޽h ? f3380___PPT10.k8D  0 L0 , ,(  , x , c $Dp   x , c $pPp p vB , NDԔ?HvB , NDԔ?H , 0޽h ? f3380___PPT10.o?+  0 L0 0 (   x  c $%p   x  c $p&pPp p vB  ND3o?` H  0޽h ? f3380___PPT10.pp  0 L0 p  (   x  c $p  p x  c $؁pPp p vB  ND3Ԕ? ` vB  ND1? @ @ vB  ND1?X X vB  ND1? P P vB  ND3Ԕ? ` H  0޽h ? f3380___PPT10.!8  0 L0 <  (  < r < S p  p r < S ȥpP p vB < ND3o?H H vB < ND3o? l H < 0޽h ? f3380___PPT10.*t;  0 L0  #(   x  c $.p  p x  c $ pPp p vB  ND3o?xxm   `p1? Recurrence score has been validated as quantifying the likelihood of distant recurrence in TAM treated patients with nod- ER+ Breast cancer H  0޽h ? f3380___PPT10.,8  0 L0    (   r  S p  p r  S 8pPp p vB  ND3Ԕ?x(xvB  ND3Ԕ? H  0޽h ? f3380___PPT10.@.V  0 L0  >(   x  c $H_p  p x  c $bpPp p    `(  ( x ( c $sp  p x ( c $ pPp p  (  `tp1?  v(Goldhirsh et al. Annals of Oncology 2005) ))H ( 0޽h ? f3380___PPT10.   0 L0  @ (   x  c $$3p0   p H  0޽h ? f3380___PPT10. dAD  0 L0 8 ,(  8 x 8 c $`Op  p x 8 c $tQpPp p  8  `Wp1? ( l EBCTG. Lancet.2005;365:1687-1717! !!vB 8 NDԔ?vB 8 NDԔ?  vB 8 NDԔ?vB 8 NDԔ?  H 8 0޽h ? f3380___PPT10.{Z  0 L0  P (   r  S p  p r  S =p D p vB  ND>?|H  0޽h ? f3380___PPT10.P2   0 L0 5    7 (     Znp33 @1?" N ,V B    fffvd @1?b[ _ ^B  6? | v  Nv @1?n , jB  B8c?0   T<3gֳgֳ?# T  ZCMF  hh88$  Z3gֳgֳ33?s & Ovarian ablation (LHRHa, RT,Surgery)' '&hh88jB  B8c? h  Tl3gֳgֳ?  @Premenopausal women (mostly with ER+ and/or PgR+) breast cancerA AF hh88   `pgֳgֳ ?<$ 0  p U   f\)31? @ GOvarian Supression/Ablation Alone as an Alternative to Chemotherapy: H H:(H  0޽h ? f33y___PPT10Y+D=' = @B +< 0 L0 ( $(  ( r ( S 3> 3 r ( S (3 `   3 H ( 0޽h ? f3380___PPT10.0R   0 L0 5    @ 3 (  @  @  `3xaxa ?  3 + @ T3gֳgֳ?;Us  Study Treatment Disease characteristics Result in terms of DFS ZEBRA G X 2 years Node+ve goserelin = CMF (n=1,640) CMF X 6 74% ER+/- in ER+ GCMF ER>20fmol N:732 OA (ooferectomy) TABLE CMF X6 N+ No difference N:600 Leuprorelin X2yr@ 0 P > :G  st HIy dB @ <8c?`B:`dB @ <1?@B:@dB @ <1?`B:`dB @ <1?( YQ( dB @ <8c?PB:PdB  @ <1?p B:p |  @ T1? ( |  @ T1? l |  @ T1?h H @ 0޽h ? f33y___PPT10Y+D=' = @B +   0 L0 5   0 " (     Z333 @1?" N ,V B    fffvd @1?b[ _ ^B  6? | v  Nv @1?n , jB  B8c?0   T 3gֳgֳ?# T  ZCMF  hh881  Z`~3gֳgֳ33?sXa 3 Ovarian ablation (LHRHa, RT,Surgery) + Tamoxifen4 43hh88jB  B8c?   T3gֳgֳ?  6Premenopausal women with ER+ and/or PgR+ breast cancer7 7hh88   `3gֳgֳ ?<$ 0  3    f`31?  QOvarian supression/ablation plus tamoxifen as an Alternative to Chemotherapy: R Rf H  0޽h ? f33y___PPT10Y+D=' = @B +< 0 L0 @H $(  H r H S l3> 3 r H S 3@`   3 H H 0޽h ? f3380___PPT10.j[  0 L0 5 VN8 (  8  8  `H3xaxa ?  3 B 8 Tt3gֳgֳ?+1  2Study Treatment Disease characteristics Result in terms of DFS ABCSG CMF X 6 Nod +/-, ER+ CMF AEdB 8 <8c? D< dB 8 <1?YQdB 8 <1?~H@~dB 8 <8c?YQH 8 0޽h ? f33y___PPT10Y+D=' = @B +x   0 L0 5 s k p  (     ZTP333 @1?" N ,V B    fffvd @1?b[ _ ^B  6? | v  Nv @1?n , jB  B8c?0   T]3gֳgֳ?# T   chemotherapy    hh88^  Zi3gֳgֳ33?sV a ( CT Ovarian ablation Tamoxifen :) # 0  hh88jB  B8c?   TO3gֳgֳ?  6Premenopausal women with ER+ and/or PgR+ breast cancer7 7hh88   `n3gֳgֳ ?<$ 0  3    fDr31?  OOvarian supression/ablation tamoxifen after Chemotherapy vs chemotherapy 8P $3T  |  T1?p@H  0޽h ? f33y___PPT10Y+D=' = @B + 0 L0 $ (   x  c $ll> l x  c $l `   l |  T1? 0H  0޽h ? f3380___PPT10.`u  0 L0 ` P (  P r P S [l  l r P S ;l  l dB P <8c?91dB P <8c?0 0dB P <8c?  dB P <8c?1)dB P <8c?dB  P <8c?X X H P 0޽h ? f3380___PPT10. ?s<  0 L0 P $(   r  S P   r  S PPp  H  0޽h ? f3380___PPT10. X   0 L0   8 @ (  8 r 8 S ]  ] r 8 S ]P ]  8  `t/1?H 0 VCT + TAM     8  `01?(  X CT +OA+TMX     2 8 Z/31?` 6IS ADD0T0ON OF OA REQU0RED?  8  `W1?   [ CT+OA+TMX/EXE  8  `(\1?T  d  X OA+TMX/EXE    2  8 Z`31?@ P  cIS THERE A NEED FOR CT?    8  `t_1?8P W CT+OA+EXE    2  8 Zi31?`p  cIS THERE PLACE FOR AI? :  8  `Xm1? 8 $TR0PTORELINCT+TAM:  $(  8  8  `:1?H  $TR0PTORELINCT+EXE,  $4   2 8 Zt31?8` \TAM OR EXE BETTER? H 8 0޽h ? f3380___PPT10.$ʭq  0 L0 <4(  r  S |   r  S }x  |  T1?p( |  T1?  |  T1? |  T1?x|   T1?  |   T1?  |   T1?  |   T1?  vB   ND3o?HHvB @ ND3o?X vB  ND3o?X8   `p1?  v(Goldhirsh et al. Annals of Oncology 2005) ))H  0޽h ? f3380___PPT10.j   0 L0   R (    s |gֳgֳ ?#" 0e      @gֳgֳ ?#" 0e  vB  ND3o?xvB  ND3o?@vB   ND3o?vB   ND3o?8|   T1?X0 |   T1?X0 |   T1? xP |  T1?8x|  T1?P  |  T1?@  |  T1?@|  T1?P|  T1? pH vB  ND3o?X x`    `X1?  v(Goldhirsh et al. Annals of Oncology 2005) ))H  0޽h ? f3380___PPT10.ȩLH 0 L0 0D 0(  D x D c $x>p> p x D c $ `   p H D 0޽h ? f3380___PPT10.   0 L0   P + (  x  c $g7   ~  s *    0t  !Anastrozole+ Tamoxifen (n=3,125)"0"   00 [?  KTamoxifen (n=3,116)0XB  0DԔw @ XB  0DԔ n   0P   _Surgery +/- RT +/- Chemo *0   0P [!  sAnastrozole (n=3,125)0  M   0TP+ Q Median follow up 68 months Almost all patients completed scheduled therapy 8P10N@,pB   HDo?y \y   ZP)P?v Ip ;5 years jB   BDԔ? P   Z\.P? S W l& 84% HR positive 39% Node positive *&1 '   `T4P1? WThe Lancet 2004 H  0޽h ? Df33I  0 p KL(    <4DPT q!Includes non breast cancer deaths""! ~  s *@HPp  P   00JP N*ITT = Intent-to-treat(2H7  7BkC~DE\FdԔ~~~~~~}}}}}}}}}}}}}}}}}}||||| | | | | | | | | | { { { { { { { { {{zzzzzzzzzzzzyyyyyyyyyyyyyyxxxxxxxxwwwwwwwwwwvvvvvvvvvvuuu u u u u u t!t!t!t!t#t#t#t#t#t#t$t$s$s$s$s$s&s&s&s&s&s&s's'r'r'r'r'r(r(r)r)r)r)q*q*q*q*q*q*q+q+p,p,p-p-p.p.p.p.o.o.o.o.o0o0o1o1o1o1o2o2n2n2n3n3n4n4n4n4m4m4m6m6m8m8m8m8l8l8l8l8l9l9l9l9k9k9k:k:k:k:j:j:j;j;j;j;j<j<j=j=j=j=j>j>i>i>i>i>i@i@i@i@iAiAhBhBhBhBgCgCgCgCgDgDgDgDgEgEfFfFfFfFfGfGfGfGfGfGfGfGeIeIeIeIeJeJeJeJdJdJdKdKcLcLcLcLcLcLcMcMcMcMcMcMbNbNbNbNbObObPbPaPaPaQaQaQaQaRaR`R`R`R`R`R`R_T_T_U_U_U_U_V_V_V_V^Y^Y^Z^Z^Z^Z^\^\]]]]]]]]]^]^]^]^\^\^\^\^\^\^\_\_\_\_\a\a[a[a[b[b[b[b[b[bZdZdZeZeZeZeZfZfZgZgYhYhYjYjYjYjYkYkYkYkXnXnXnXnXoXoXoXoXoXoWoWoWoWoVpVpVqVqVqVqUsUsUsUsUsUsUtUtTtTtTuTuTuTuTuTuSvSvSvSvSvSvSwSwSwSwRxRxRyRyRzRzRzRzR{R{Q{Q{Q|Q|Q}Q}P}P}P}P}PPPPOOOOOONNNNNNNNMMMMMMLLLLLLKKKKKKKKKKJJJJJJJJIIIIIIIIIIIIIIHHHHHHHHHHGGGGGGFFFFFFFFEEEEEEEEEEDDDDDDCCCCCCCCBBBBBBBBBBBBAAAAAAAAAA@@@@@@@@@@????????>>>>>>>>========<<<<<<<<<<;;;;;;;;;;;;::::::999999999988888888887777777766666666555555555555554444333333332222222222221111111111000000000000//////////............----,,,,,,,,,,++++++++++********))))))))))((((((((((''''''&&&&&&&&&&&&&&&&&&%%%%%%%%%%%%%%$$$$$$$$$$$$######################""""""""""""""!!!!!!!!!!!!                                                    !!!!!!!!!!""""""""########$$$$$$$$$$%%%%&&&&&&&&''''''(((((((((())))**********++++++++++,,,,,,,,--------..........//////////00000000001111111111222222223333333333444444444444445555556666666666777777777777888888888899999999:::::::::::::: ; ; ; ; ; ; ; ; ; ; < < < < < < < < = = = = = = = = = = = = = = > > > > > > > > > > ? ? ? ? ? ? ? ? @ @ @ @ @ @ @ @ @ @ @ @ A A A A A A A A B B B B B B B B B B C C C C C C C C C C D D D D D D D D E E E E E E E E E E F F F F F F F F F F G G G G G G G G G G G GHHHHHHHHHHHHIIIIIIJJJJJJJJKKKKKKKKKKLLLLLLLLLLMMMMMMMMMMNNNNNNNNNNOOOOOOPPPPPPPPQQQQQQQQQQRRRRRRRRSSSSSSSSSSTTTTTTTTUUUUUUUUUUVVVVVVWWWWWWWWWWXXXXXXXXYYYYYYZZZZZZZZZZ[[[[[[[[[[\\\\\\\\]]]]]]]]^^^^^^^^^^________``````````aaaaaabbbbbbbbbbccccccccddddddddddeeeeeeeeeeffffgggggggggghhhhhhhhhhhhiiiiiiiijjjjjjjjjjkkkkkkkk @ h9  @9BkCDElFtԔ  !!!!""""####&&&&''(((((())))********,,--////00001111112222334444444444555555778888889999;;;;;;;;;;~<~<~<~<~<~<~<~<}=}=}>}>}>}>}>}>|>|>|@|@|@|@{@{@{A{A{B{B{B{BzCzCzCzCzDzDyDyDyEyEyFyFyGyGyGyGxGxGxGxGxHxHxHxHwHwHwIwIvIvIvJvJvKvKvKvKuLuLuLuLuLuLtMtMtMtMtMtMtOtOtOtOsPsPsPsPsPsPsQsQrQrQrRrRqRqRqRqRqSqSqSqSpTpTpTpTpUpUpUpUpUpUoVoVoVoVnVnVnWnWnWnWnXnXmXmXmXmXmYmYmYmYmZmZlZlZl[l[l\l\l\l\l]l]k]k]k]k]k]k]k^k^j_j_j_j_j`j`i`i`i`i`i`i`iaiaiaiahbhbhbhbhdhdheheggggggggggggggggghghfhfhfjfjfjfjfjfjekekekekdldldldldldldldldmdmcmcmcmcmcncnbnbnbnbnbobobpbpaqaqarararararar`s`s`s`s`t`t`t`t`t`t_u_u_u_u_u_u_v_v^w^w^w^w^x^x^x^x^y^y]z]z]z]z]{]{]|]|]}]}\}\}\\\\[[[[[[ZZZZZZZZZZZZZZYYYYYYYYYYXXXXXXWWWWWWWWWWVVVVVVVVVVUUUUUUTTTTTTTTTTSSSSSSSSRRRRRRRRRRQQQQQQPPPPPPOOOOOONNNNNNMMMMMMMMLLLLLLLLLLKKKKKKKKJJJJJJJJJJIIIIIIIIHHHHHHGGGGGGGGGGFFFFFFFFEEEEEEEEEEDDDDDDDDDDDDCCCCCCBBBBBBBBBBBBAAAAAA@@@@@@@@@@@@??????????>>>>>>>>==========<<<<<<<<<<<<;;;;;;;;::::::::999999999999888888887777777777666666665555555555444444333333333322222222221111110000////////////......----------,,,,,,,,,,,,,,,,++++++++++++++********))))))))))))))))))))))))))))((((((((((((''''''''''&&&&&&&&&&&&&&&&&&%%%%%%%%%%$$$ $ $ $ $ $ $ $ # # # # # # # # # # # # # # # # # # ########""""""""""""""""""!!!!!!!!!!!!                    !!!!!!!!""""""""######$$$$$$$$$$%%%%%%&&&&&&&&''''''''''(((())))))))))************++++++++++,,,,,,------............//////////00000000001111111122222222223333333333334444444444445555556666666677777777888888888899999999::::::::::::;;;;;;;;<<<<<<<<<<==========>>>>>>>>?? ? ? ? ? ? ? ? ? @ @ @ @ @ @ @ @ @ @ @ @ A A A A A A A A B B B B B B C C C C C C C C C C D D D D D D D D E E E E E E E E E E F F F F F F F F F F G G G G G G G G H H H H H H H H H H I I I I I I J J J J J J J J K K K K K K K K K K L L L L L L L L M M M M M M M M M M N N N N N N N N N N O O O O O O O O P P P P P P P P P P Q Q Q Q Q Q Q Q Q Q Q Q R R R R R R R RSSSSSSSSSSTTTTTTTTTTUUUUUUUUUUVVVVVVVVWWWWWWWWWWXXXXXXXXYYYYYYZZZZZZZZZZ[[[[[[[[[[[[\\\\\\\\]]]]]]]]^^^^^^^^^^________````````````aaaaaaaabbbbbbbbbbccccccccddddddddddeeeeeeeeeeffffgggggggggghhhhhhhhhhiiiiiiiijjjjjjjjjjkkkkkkkk78@ :B  3 |* [   6x1P |6 dAt risk:,      6!P=2 ]A,      6YP2 b3125.      6]P2 b3004.      6$bPK 2 b2874.      6gP Q 2 b2757.     6cP 2 b2645.     6jP2 b2350.     6,oPjZ2 a984.     6yP2 ]T,     6P b3116.     6P b2992.     6` PK  b2835.     6P Q  b2709.     6P  b2575.     6y b2273.     6diY a933.     6=  # jFollow-up time (years)$   :B  3 |FG& :B @ 3 | A   6ȉ} *  ]0,     6<   ]5,   :B @ 3 |A  6<N ^10,   :B  @ 3 |A ! 6X NC ^15,    " 6N ^20,   :B #@ 3 |A $ 6 UN ^25,    % 6u t"  [0*   :B & 3 |* \][  ' 6xu 9"  [1*   :B ( 3 |*   [  ) 6#u C "  [2*   :B * 3 |* [  + 6T&u  "  [3*    , 6*u o"  [4*   :B - 3 |* XY[  . 64/u 5"  [5*   :B / 3 |*  [  0 64u ="  [6*   XB 1 0D|& @& :B 2 3 |* [ :B 3@ 3 |0 A1 :B 4@ 3 |UAV 5 Z1?  X @` 6 < <m AHR 0.87h 7 < <A vs T  8 <A>  $95% CI (0.78 0.97)Fhl3 #B 9 C xD8c?" B : C xD8c?" B ; C xD8c?" R < s *Ao@ _:B = 3 Ԕ, > 6H Z yAnastrozole (A),     ? 6tQu 1 w Tamoxifen (T),     :B @ 3 Ԕ,XB A 0Do 6 XB B 0Do6 XB C 0Domm6 XB D 0Do0  E 0V ! 7  LAbsolute difference:`  F <[c R 7  :1.5% G <4`c 7  :2.0% H <cc }7  :2.4% I <l^c y7  :2.9% J <$k % P p-value 0.01( hl3  K <>o "  ` Patients (%)$    H  0޽h ? Oa(,  0 L0 Ċ AAT(  ~  s *m_     <(w{ q!Includes non breast cancer deaths""! h1  @1BkC\DElFtԔ\\\\\\[[[[[[[[[[[[[ [ [ [ [ [ [ [ [ [ [[[[[[ZZZZZZZZZZZZZZZZZZYYYYYYY Y Y Y Y!Y!X!X!X#X#X#X#X$X$W$W$W$W$W&W&W(W(W*W*W+W+W,W,V.V.V.V.V.V.V/V/V0V0U0U0U1U1U2U2U2U2U2U2U2U2T3T3T4T4T6T6T7T7T8T8S9S9S:S:S:S:S:S:R;R;R<R<R<R<R=R=R>R>R@R@Q@Q@QCQCQCQCQCQCQDQDQDQDQFQFQFQFPGPGPGPGPGPGPJPJOJOJOKOKOLOLNMNMNNNNNPNPNQNQNQNQMRMRMRMRMRMRMSMSMTMTMUMULULULULULVLVLVLVLYLYKZKZK[K[K[K[K\K\K]K]K^K^K^K^K^K^K^K^K`K`JbJbJbJbJbJbJdJdJeJeJeJeIfIfIgIgIgIgIgIgHhHhHhHhHiHiHiHiHjHjGkGkGkGkGkGkGnGnGnGnGnGnGoGoGoGoFoFoFpFpEqEqEqEqEqEqErErErErDsDsDsDsDtDtDtDtDuDuDuDuCuCuCvCvCwCwCwCwCxCxBzBzB{B{B{B{A}A}A~A~AAAA@@@@@@@@@@@@@@??????????>>>>>>>>>>================<<<<;;;;;;;;;;;;::::::::999999998888888888888888777777777766666666555555444444333333332222222222111111111111111111000000////////............--------------,,,,,,++++++++++++++************))))))))))))((((((((''''''''''&&&&&&&&&&&&%%%%%%%%$$$$$$$$$$$$$$$$$$$$$$$$######################""""""""""!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!                                                            !!!!!!!!!!""""""""""########$$$$$$$$$$%%%%%%&&&&&&&&&&''''''(((((((())))))**********++++++++++,,,,,,,,----------..........//////////00000000000011111111112222222233333333334444444444444455555566666666667777777777888888888899 9 9 9 9 9 9 : : : : : : : : : : : : : : ; ; ; ; ; ; < < < < < < < < = = = = = = = = = = = = = = > > > > > > > > > > ? ? ? ? ? ? @ @ @ @ @ @ @ @ @ @ @ @ A A A A A A A A B B B B B B B B B B C C C C C C C C C C D D D D D D D D E E E E E E E E E E F FFFFFFFFFFFGGGGGGGGHHHHHHHHHHIIIIIIJJJJJJJJKKKKKKKKKKLLLLLLLLLLMMMMMMMMMMNNNNNNNNNNNNOOOOOOPPPPPPPPQQQQQQQQQQRRRRRRRRSSSSSSSSSSTTTTTTTTUUUUUUUUUUVVVVVVVVVVWWWWWWWWWWXXXXXXXXYYYYYYZZZZZZZZZZ[[[[[[[[[[\\\\\\\\]]]]]]]]]]^^^^^^^^^^______``````````aaaaaaaabbbbbbbbbbccccccccddddddddddeeeeeeeeeeffffgggggggggghhhhhhhhhhhhiiiiiiiijjjjjjjjjjkkkkkkkk7 8 @u 0  0BkC_DE FԔ_________ _ ^ ^ ^ ^ ^ ^ ^^^^^^^^^^^^]]]]]]]]]]]]\\\\\\\\\\\\\\\\\\\\\ \ \ \ [![![![!["["["["[#[#[#[#[&[&[&[&Z&Z&Z'Z'Z)Z)Z*Z*Z*Z*Z*Z*Y,Y,Y-Y-Y-Y-Y/Y/Y1Y1X1X1X2X2X4X4X5X5X5X5X7X7W7W7W9W9W;W;W<W<W<W<V>V>V?V?V@V@VAVAVAVAUBUBUCUCUEUEUGUGUHUHTITITJTJTJTJTKTKSNSNSPSPSPSPSQSQRQRQRRRRRRRRRRRRRRRRQSQSQSQSQTQTQTQTPUPUPWPWPWPWPWPWPXPXPYPYP[P[O[O[O_O_O`O`O`O`N`N`NaNaNaNaNbNbNbNbMdMdMdMdMeMeMeMeMfMfLgLgLhLhLlLlLmLmKmKmKnKnKnKnKoKoKqKqKqKqKsKsJuJuJvJvJvJvJvJvJwJwJxJxJxJxIyIyIyIyIyIyHzHzHzHzHzHzH{H{H{H{G|G|G|G|G|G|G|G|G~G~FFFFFFFFFFEEEEEEDDDDDDDDDDDDDDCCCCCCBBBBBBAAAAAA@@@@@@????????????>>>>>>>>========<<<<<<<<<<;;;;;;;;;;::::::::::::::9999999999888888777777776666666666666655555555554444444444443333333333332222111111111111110000000000////////..........----------------,,,,,,,,++++++++**********))))))))))))((((((''''''''''''&&&&&&&&&&&&%%%%$$$$$$$$########""""""""""""!!!!!!!!!!!!                                       !!!!!!!!""""""""######$$$$$$$$$$%%%%&&&&&&&&''''''(((())))))**********++++++++++,,,,,,----............//////////0000000000111111112222222222333333333344444444444455555566666666777777778888888888999999::::::::::::;;;;;;;;<<<< < < < < < < = = = = = = = = = = > > > > > > > > ? ? ? ? ? ? ? ? @ @ @ @ @ @ @ @ @ @ @ @ A A A A A A A A B B B B B B C C C C C C C C C C D D D D D D D D E E E E E E E E E E F F F F F F F F F F F F F F G G G G G G G G H H H H H H H H H H I I I I I I J J J J J J J J K K K K K K K K K K L L L L L LLLMMMMMMMMMMNNNNNNNNNNNNOOOOOOOOPPPPPPPPPPQQQQQQQQQQRRRRRRSSSSSSSSSSTTTTTTTTTTUUUUUUUUUUVVVVVVVVWWWWWWWWWWXXXXXXXXYYYYYYZZZZZZZZZZ[[[[[[[[[[\\\\\\\\]]]]]]]]^^^^^^^^^^^^______``````````aaaaaaaabbbbbbbbbbbbccccccccddddddddddeeeeeeeeeeffffgggggggggghhhhhhhhhhhhiiiiiiiijjjjjjjjjjkkkkkk  @R   6pyao i  dAt risk:,     6\a a ]A,     6a ! b3125.      6La  b3051.      6ȍa Y u  b2956.      6ؒa '  b2865.      60a  b2784.      6la ]y b2479.     6a % b1037.     6ay X ]T,     6ay! b3116.     6ay b3048.     6(ayY u  b2972.     6ay '  b2872.     6$ay b2747.     6ay^z b2461.     6,ay$ b1037.   :B  3 |! P   6a    pFollow-up time (years)*   :B  3 |?@ :B @ 3 | ;   6 az '  ]0,     6Ta   ]5,   :B @ 3 |;  6aWO  ^10,   :B @ 3 |;   6daOm ^15,    ! 64ta4O ^20,   :B "@ 3 |; # 6$kaOJ ^25,    $ 6ai l  [0*   :B % 3 |! >?P  & 6`ai l  [1*   :B ' 3 |! P  ( 6%ai    [2*   :B ) 3 |! P  * 6!ai q   [3*    + 6.ai e  [4*   :B , 3 |! P  - 6X4ai   [5*   :B . 3 |! P  / 6Dai k  [6*   XB 0 0D| : :B 1 3 |! @@P :B 2@ 3 |9 ;: :B 3@ 3 |; 4 Z`Ia1? = X @` 5 <SaI  AHR 0.97h 6 <Wa#   <A vs T  7 <[a Z  $95% CI (0.85 1.12)Fhl3 #B 8 C xD8c?"B 9 C xD8c?"B : C xD8c?"R ; s *Ao y:B < 3 Ԕ)q* = 6Daa  yAnastrozole (A),     > 6pa[ S w Tamoxifen (T),     :B ? 3 Ԕq @ <0=a  f Patients (%)*     A <aj   O p-value 0.7( hl3 H  0޽h ? Oa( 0 L0 &p T(  T T  6FS"    l{  F  T  6 FS"      F (H}P;PB T s *޽h ? ̙33y___PPT10Y+D=' ]= @B +   0 L0 ~ v  ` (  ` ` TF8c?   cPrimary surgery +/- RTx   ` TF8c? s  e TAM 3 years n=1,606    ` TpF8c?) f  7Total patients n=3,224 ABCSG 8 n=2,262 + ARNO 95 n=962(8  8  ` TF8c?  ^  e ANA 3 years n=1,618    ` TP$F8c?    o+ TAM 2 years . x   vB ` NDԔ?  vB ` NDԔ?. <  / pB  ` HDԔ? , < pB  ` HD8c?< = 9 ~  ` s *8)F  F vB  ` NDԔ?4    `  `*F1?T P m#Jakesz R et al Lancet 2005; 366:455$ $$H ` 0޽h ? ___PPT10i.v`V<+D=' ]= @B +}  0 L0 || mV|(  l~ l s *2F`  F  l T3F8c?  W#*Zero point = 2 years after surgery$ $:B l 3 |cf :B l 3 |A B :B l 3 |  :B l 3 |N O :B l 3 |:B  l 3 |WX:B  l 3 |:B  l 3 |cd:B  l 3 |A B :B  l 3 |A g :B l 3 |A g :B l 3 |A g :B l 3 |A g :B l 3 |A g :B l 3 |A g :B l 3 |cg:B l 3 |gh:B l 3 |gk:B l 3 |kl:B l 3 |cg:B l 3 |gh:B l 3 |kp:B l 3 |pp:B l 3 |px:B l 3 |x|:B l 3 ||}:B l 3 ||:B l 3 |&:B  l 3 |&':B !l 3 |&+:B "l 3 |+9:B #l 3 |99:B $l 3 |9S:B %l 3 |ST:B &l 3 |ST:B 'l 3 |ST:B (l 3 V:B )l 3 |gk:B *l 3 |k=l:B +l 3 |k=>p:B ,l 3 |p=Op:B -l 3 |pOPx:B .l 3 |xOSx:B /l 3 |xST|:B 0l 3 ||S}:B 1l 3 ||:B 2l 3 V:B 3l 3 V:B 4l 3 V:B 5l 3 V:B 6l 3 Vp:B 7l 3 Vpq:B 8l 3 Vpz:B 9l 3 Vz{:B :l 3 Vz:B ;l 3 V:B l 3 V:B ?l 3 V:B @l 3 V:B Al 3 V:B Bl 3 V8:B Cl 3 V89:B Dl 3 V8E:B El 3 VEF:B Fl 3 VES:B Gl 3 VST:B Hl 3 VSX:B Il 3 VXY:B Jl 3 VX:B Kl 3 V:B Ll 3 V:B Ml 3 V:B Nl 3 V:B Ol 3 V:B Pl 3 V :B Ql 3 V :B Rl 3 V :B Sl 3 V:B Tl 3 V:B Ul 3 VC:B Vl 3 VCD:B Wl 3 VC:B Xl 3 V:B Yl 3 V:B Zl 3 V:B [l 3 V+ :B \l 3 V+ + :B ]l 3 V+ X :B ^l 3 VX Y :B _l 3 V X \ :B `l 3 V \ ] :B al 3 V\ i :B bl 3 Vi j :B cl 3 Vi :B dl 3 V :B el 3 V  !:B fl 3 V  (:B gl 3 V( ):B hl 3 V( 0:B il 3 V0 # 1:B jl 3 V0# $ 9:B kl 3 V9# p ::B ll 3 V9p q A:B ml 3 VAp B:B nl 3 VA J:B ol 3 VJ K:B pl 3 VJ R:B ql 3 VR S:B rl 3 VR _:B sl 3 V_ p _:B tl 3 V_p q h:B ul 3 Vhp h:B vl 3 Vh t:B wl 3 Vt u:B xl 3 Vt |:B yl 3 V| }:B zl 3 V| :B {l 3 V 8 :B |l 3 V8 8 :B }l 3 V8 @ :B ~l 3 V@ A :B l 3 V@ :B l 3 V :B l 3 V :B l 3 V :B l 3 V :B l 3 V:B l 3 V7:B l 3 V78:B l 3 V7I:B l 3 VIJ:B l 3 VI:B l 3 V:B l 3 V:B l 3 V:B l 3 V:B l 3 V:B l 3 V:B l 3 V0:B l 3 V01:B l 3 V0F:B l 3 VF G:B l 3 VF !_:B l 3 V_ B`:B l 3 V_BC|:B l 3 V|BT}:B l 3 V|TU:B l 3 VT:B l 3 V:B l 3 V:B l 3 V:B l 3 V:B l 3 V:B l 3 V:B l 3 V:B l 3 V:B l 3 V:B l 3 V :B l 3 V :B l 3 V l:B l 3 Vlm:B l 3 Vl:B l 3 V93L 3Y[ l# xBB l 3 VBB l 3 V^BB l 3 V^_%BB l 3 V^%&BB l 3 V%7BB l 3 V7S8BB l 3 VS7TOBB l 3 VSOPBB l 3 VOfBB l 3 VfgBB l 3 Vf~BB l 3 V~BB l 3 V~BB l 3 VBBB l 3 VBCBB l 3 VBZBB l 3 VZ[.N 3Y l 3YBB l 3 V v: wBB l 3 V: v; BB l 3 V:  BB l 3 V  BB l 3 V BB l 3 VBB l 3 VTBB l 3 VTUBB l 3 VT]BB l 3 V]^BB l 3 V]lBB l 3 VlmBB l 3 VlmBB l 3 VlmBB l 3 VluBB l 3 VuvBB l 3 VuBB l 3 VBB l 3 VBB l 3 Vh(N 3Y v l 3Y vBB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V 9 BB l 3 V9 : BB l 3 V9 > BB l 3 V> ? BB l 3 V>  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  &BB l 3 V & 'BB l 3 V & 0BB l 3 V 0 1BB l 3 V 0! >BB l 3 V >. ?BB l 3 V. >/ GBB l 3 V. G HBB l 3 V G QBB l 3 V Q RBB l 3 V Q _BB l 3 V _ `BB l 3 V _ hBB l 3 V h iBB l 3 V h v^N 3Y  l 3Y BB l 3 VU } ~BB l 3 V } BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V  BB l 3 V a BB l 3 Va b BB m 3 Va  BB m 3 V  BB m 3 V  BB m 3 V  BB m 3 V  BB m 3 V  N 3YV } m 3YV }N \-V } m \-V }BB m 3 V\-x.BB  m 3 Vx-y7BB  m 3 Vx78BB  m 3 V7@BB  m 3 V@ABB  m 3 V@EBB m 3 VEFBB m 3 VENBB m 3 VNOBB m 3 VNWBB m 3 VWXBB m 3 VW\BB m 3 V\ ]BB m 3 V \ fBB m 3 V f* gBB m 3 V* f+ jBB m 3 V* j+ kBB m 3 V* j+ tBB m 3 V* tU uBB m 3 VU tV } N 3Yn- m 3Yn- N 3Y> m 3Y>N 3Y m 3YBB m 3 |3YEZBB  m 3 |bhclBB !m 3 |BB "m 3 |BB #m 3 |BB $m 3 |BB %m 3 |BB &m 3 |BB 'm 3 |BB (m 3 |BB )m 3 |BB *m 3 |BB +m 3 |BB ,m 3 |BB -m 3 V?BB .m 3 V?@BB /m 3 V?CBB 0m 3 VCDBB 1m 3 VCVBB 2m 3 VVWBB 3m 3 VVBB 4m 3 VBB 5m 3 VBB 6m 3 VBB 7m 3 VBB 8m 3 VBB 9m 3 VBB :m 3 VBB ;m 3 VBB m 3 VBB ?m 3 VBB @m 3 VBB Am 3 V=BB Bm 3 V=>BB Cm 3 V=gBB Dm 3 VghBB Em 3 VgBB Fm 3 VBB Gm 3 VBB Hm 3 VBB Im 3 VBB Jm 3 VBB Km 3 VBB Lm 3 VBB Mm 3 VBB Nm 3 V BB Om 3 V ; BB Pm 3 V; <BB Qm 3 V;?BB Rm 3 V?@BB Sm 3 V?RBB Tm 3 VRSBB Um 3 VRS BB Vm 3 VRS(BB Wm 3 VR(\)BB Xm 3 V\(]-BB Ym 3 Vjn:B Zm 3 Vl:B [m 3 Vlm :B \m 3 V l!:B ]m 3 V F ^m 6` e  G0*  _m 68 e1  H75*  `m 6T e  H80*  am 6pe? H85*  bm 6e H90*  cm 6eF H95*  dm 6$ vf I100*  em 6l `  G0*  fm 6 `  K1.  gm 6$ `  K2.  hm 6 `  K3.  im 6 `  K4.  jm 6  `  K5.  km T%8c?: LEvent-free survival (%) W lm TH*8c? `<  1ANA vs TAM p=0.0009 HR 0.60 [95% CI 0.44-0.81] N2  0  mm T828c?6 0 HEFS time in years* :B nm 3 | W pB om HD|?A ~ pB pm HD|?   qm Tl78c?N ]ANA  2  rm T;8c? ]TAM  2  sm 0?f L bAt risk:*    tm 6=+S `1606,    um 0H+O _343,    vm 6L+2" _176,    wm 6|Q0 ]TAM*    xm 6`V ]ANA*    ym 6Z\ `1618,    zm 6@_+8x `1217,    {m 6c@ `1243,    |m 6Hh* v  _858,    }m 6m v  _874,    ~m 6j0I 9 _593,    m 6qI 9 _623,    m 0PuN _375,    m 6y:* _178,   H l 0޽h ? y___PPT10Y+D=' ]= @B +d  0 L0  L(   ~  s *\ů   ~  s *ʯPp    6˯X} b2-3 year tamoxifen0R2  s * ?   64 0  ^ 2-3 year TMX 0    6{ P   ^ 2-3 year EXE 0    6x *0 I \ 266 event  0    6$ tI [ 183 event 0  R2  s **F -V R2  s ** p&V    `1?  o!Coombes et al. NEJM 2004;350,1081" ""H  0޽h ? 333380___PPT10.Wc "  0 L0 zr  $  (   ~  s *K   Lx   $  #"*    <\K?  T @`   <ЬK?I  T @`   64KW"?I  X @`   <TK?c  ^20 @`   <K?I c  ]9 @`   6KW"?c I  zContrlateral breast cancer @`   <hK? c  _106 @`   <d|K?I c  ^93 @`   6KW"? I c  edeath @`   <K?   }86.8%, 4,7% p=0.00005  * @`   <$dK?I   a91.5% @`   6fKW"?I  k DFS 3. year    @`   <(K?  _266 @`   <0K?I  _183 @`   6PKW"?I  eevent @`   62K?  lTamoxifen N:2380 @`   6\K?I  mExemestan N:2362 @`   < K?I  T @``B   0o ? ZB   s *1 ? ZB   s *1 ? ZB   s *1 ?  ZB   s *1 ?c c ZB   s *1 ? `B   0o ? `B   0o ?ZB   s *1 ?I I ZB   s *1 ?`B   0o ?  H  0޽h ? 333380___PPT10.0U  0' L0 x@ (   ~  s *8K  K   6,1K  "  c _ж_ж @1?c"$ `?    c _ж_ж @1?c"$ `?   3 rK_ж_ж 1?#"  jQ [ Tamoxifen" 0 '    3 rK_ж_ж 1?#"    `5 years adjuvant 0  B  C x_ж_жDjJ?"e  e   c _ж_жv @1?c"$ ? J F   3 rK_ж_ж 1?#"  OI 6  [ Letrozole" 0 '  B  # l_ж_жD1?"fB  # l_ж_жD1?"   3 rw0_ж_ж 1?#"  kR  [ Tamoxifen" 0 '  B  C x_ж_жDjJ?"f > Rf `  3 rDx0_ж_ж 1?#"   + 9 V5 more years  extended adjuvant Letrozole$,0, , 2   _ж_жvd @1?#"  xl t   `l601?| * Goss et al. N Engl J Med. 2003;349:1793. T+   B   ;   =0_ж_жv @1?c"$ ?r n Oplacebo H  0޽h ? f3ff3___PPT10i.o+D=' ]= @B +   0 L0 `"" n(   x  c $>0  0   3 rLF0_ж_ж 1?#" `0 J  G r    # #"@    N 0?  Z@`   N 0?Z   Z@`   N0?& Z   g132  @`   Ne0?&   b75  @`   Nm0?  dEvents  @`   N0?0 g0.00008  @`   Nl%0?Z 0  0.57 (0.43 0.75)  @`   N-0?& 0Z  g87%  @`   N$?0&  c93%  @`   N$?0 m4-Year DFS Rate  @`   N|$?0 P Value0  @`   Nب$?Z 0 Hazard Ratio (95% Cl)&   @`   N ?& Z 0 vPlacebo (n = 2582)  @`   N?& 0 tLetrozole (n = 2575)  @`   Hx?0 X@``B   0o ?ZB   s *1 ?  `B   0o ?0`B   0o ?0`B   0o ?& `B   0o ?0`B   0o ?& Z `B   0o ?Z `B   0o ?`B   0o ?0`B   0o ? `B   0o ? ZB   s *o ?00ZB !  s *1 ? " 3 r|_ж_ж 1?#" `D    = Letrozole decreased the risk of recurrence by 43% versus placebo Median duration of follow-up was 2.4 years when events (207) reached the preplanned interim analysis point (171)V@ CgtGg  H  0޽h ? qq=___PPT10i.^зf+D=' 3= @B +K  0 L0 ZR#$ (   ~  s *&0  0   s *f0/ 0 E  8mu  3 r$_ж_ж 1?#"  4 -Goss et al. N Engl J Med. 2003;349:1793-1802.H.0 ' ''&   r    # #"@    N4?  Z@`   N?Z   Z@`   N?& Z   f42  @`   N]?&   b31  @`   NX:?  dEvents  @`   N`C?0 c.25  @`   NR?Z 0  0.76 (0.48 1.21)  @`   NE?& 0Z  g94%  @`   NS?0&  c96%  @`   Nԛ?0 l4-Year OS Rate  @`   Np?0 P Value0  @`   NR?Z 0 Hazard Ratio (95% Cl)&   @`   NR?& Z 0 vPlacebo (n = 2582)  @`   NR?& 0 tLetrozole (n = 2575)  @`   H%R?0 X@``B   0o ?ZB   s *1 ?  `B   0o ?0`B   0o ?0`B   0o ?& `B   0o ?0`B   0o ?& Z `B   0o ?Z `B   0o ?`B   0o ?0`B   0o ? `B   0o ? ZB !  s *o ?00ZB "  s *1 ?; # H2R    gLetrozole decreased the risk of death by 24% versus placebo Median duration of follow-up was 2.4 yearshh h  8mH  0޽h ? ̙33y___PPT10Y+D=' 3= @B +   0' L0  Q(   ~  s *<0 08     s *     8mu  3 r\S_ж_ж 1?#" `4 -Goss et al. N Engl J Med. 2003;349:1793-1802.H.0 ' ''&   |l s    #"s    NIR?s  g0.003B  @`   NR?@ s  f0.60B  @`   NR?x@ s  z!40%*bB  @`   N R?xs  pNode+ (n = 2370)B  @`   NtR? \B @`   NR?@  f0.47B  @`   NR?x@  z!53%*bB  @`   NjR?x  Node (n = 2581)B  @`    NȄR? P Value6BBB  @`   N8~R?@  dHRB  @`   NDR?x@  tRisk of RecurrenceB  @`   NLR?x ZB@``B   0o ?xZB   s *1 ?s s `B   0o ?`B   0o ?`B   0o ?x@ `B   0o ?`B   0o ?@ `B   0o ?`B   0o ?`B   0o ?s `B   0o ?s ZB   s *o ?ZB   s *1 ?H  0޽h ? f3ff3___PPT10i.d5z+D=' = @B +7  0 L0 p(  r  S ܬR  R r  S $RPp R   ZR1?h Qinitial (  ZR1?`(  X sequential   (   ZlR1? p  Rextended    B2   `ĶR1?X  ^Best time To Start an Aromatase 0nhibitor ???"0 ,0H  0޽h ? f3380___PPT10.cT  0 L0 d <(  d ~ d s * R  R ~ d s *RPp R H d 0޽h ? 333380___PPT10.+@^  0 L0 -%h (  h ~ h s *lR  R  h  6DR S" Pp R  h 6R % XBIG 1-98 0   h 6R*  &  Y NSABP B33 0   h 6R:-F   TTEAM0H h 0޽h ? 333380___PPT10.30E  0 L0 t -(  t ~ t s *   ~ t s *8Pp   t Z1? ` _Winer E et al. JCO 2005 H t 0޽h ? 333380___PPT10.- ~e.< 0 L0  $(   r  S L>  r  S X `    H  0޽h ? f3380___PPT10.?  0 L0  (   ~  s *p   v    # #""    <?A  ~45% / 35% P=0.022$  @`   <Y?y A }55% / 36% P<0.001$  @`   <l]? y  e154/170 @`   <l?  rLetrozole/ tamoxifen @`   <?A   _- @`   <h ?y  A  n40% / 35% P=0.29 @`   <|#? y  e228/223 @`   <+?   tAnastrozole/ tamoxifen @`   <Hh?A   }46% / 22% P=0.03$  @`   <tq?y A  g 37% / 36%    @`   <|z?y   e113/108 @`   <,?  tAnastrozole/ tamoxifen @`   6?A  uBreast conserving surgery @`   6?y A i Response rate @`   6$?y  ]n @`   6H? T @``B   0o ? ZB   s *1 ? ZB   s *1 ?  ZB   s *1 ?  `B   0o ? `B   0o ?ZB   s *1 ?ZB   s *1 ?y y ZB   s *1 ?AA`B   0o ?  H  0޽h ? 333380___PPT10.;K.<  0' L0 KCh (  h ~ h s *Pn>    h Bĉ   4 <y -g+W^B h 6D3oUFU h 6] =` Ellis et al. J Clin Oncol. 2001<     H h 0޽h ? 'ggg1e((###y___PPT10Y+D=' = @B +H 0 L0 `P 0(  P x P c $̉>  x P c $͉ `    H P 0޽h ? f3380___PPT10. 0l  0 L0 5 pT 4(  T @ T T0Չgֳgֳ?  bKlijn JGM, et al. J Clin Oncol 2001; 19: 343 53. 2 2hh88 T Z(߉? ] Parameter  hh88 T Z?+ LHRH agonist (n=256)8  hh88 T T?  ` LHRH agonist  hh88 T Tt ? @5  + tamoxifen (n=250)D  hh88 T ZP?a a Odds/hazard   hh88 T Z?)u [ratio hh88  T Z\? 4 ip value( hh88  T Z1?Y ^ OR (CR+PR)  hh88  T Z(3?Y W30% hh88  T T<? Y W39% hh88  T ZL ?Y Z0.67 hh88 T Z ?cY X0.03 hh88 T ZB ?e%  ` PFS (median)  hh88 T ZS ?e %  ^ 5.4 months  hh88 T T] ?e %  ^ 8.7 months  hh88 T Z`_ ?e%  Z0.70 hh88 T Z) ?e%  Z<0.001 hh88 T Zq ?0   _ OS (median)  hh88 T Z({ ?0 j  ] 2.5 years  hh88 T T8 ?0   ] 2.9 years  hh88 T Z ?0   Z0.78 hh88 T Z̐ ?0 c  X0.02 hh88dB T <8c?H@dB T <8c?P H@P dB T <1?PUMP T  ` gֳgֳ ?    T  `\, gֳgֳ ?U p   7 T T gֳgֳ?  kOR = Objective response PFS = Progression-free survival OS = Overall survival Median follow-up of 6.8 yearsl l ,H T 0޽h ? f33y___PPT10Y+D=' = @B ++  0 L0 **66\ l*(  \ ~ \ s *P    (~ 1 \ # #"*h1 \  < ?   9.4* 6.0D FfF  @` \  < ?   49* 38DFfF @`4 \  <k ?   32* 21fFf&f  @` \  < ?   i453 454B @` \  <  ?*   Letrozole TamoxifenNFBB @`  \  <Դ ? *  Mouridsen JCO 2001,2003 . BB @`  \  64 ?  %Median time to progression (months):&@@& @`  \  6t ?   Clinical benefit - %2`@ @`  \  6 ?   y Response rate$ @ @`  \  6 ?  mn$@ @` \  6D ?*  \B  @` \  6~P ?*  ZB  @` \  <$P ? y1 \B  @` \  <LP ? ey e66 49 @` \  <,P ? P e g56 56B @` \  <|P ? P  59* 468BbB @` \  <TP ?y1 \B  @` \  <(P ? y 1 \B  @` \  <P ?y 1 Z  @` \  <P ?*y1 \B  @` \  <P ?y*1 ZB  @` \  <P ?ey h9.9 5.8    @` \  <pP ? e y h46* 31 @` \  <(P ?e y g182 189 @` \  < P ?*ey Exemestane tamoxifen&   @` \  <0f ?e*y rParidaens ASCO 2004 @` \  <P ?P e i8.2 8.3B @` \  <贱 ? P e g33 33B @`  \  <ȯ ?P e i340 328B @` !\  <ؿ ?*P e Anastrozol Tamoxifen@ F3BB @` "\  <`ձ ?P *e Bonneterre Cancer, 2001 . B B @`  #\  < ? P   11.1* 5.6D FfF  @` $\  <tϱ ? P  g21 17B @` %\  < ? P  i171 182B @` &\  <a ?* P  Anastrozol Tamoxifen@ F3BB @` '\  <(a ? *P  Nabholtz JCO 2000 . B B @`fB (\  6o ?`B )\  01 ?P P `B *\  01 ?ee`B +\  01 ?yyfB ,\  6o ?11fB -\  6o ?1`B .\  01 ?**1`B /\  01 ?1`B 0\  01 ?  1`B 1\  01 ?  1fB 2\  6o ?1`B 3\  01 ?1`B 4\  01 ?  `B 5\  01 ?  $ 6\ Za1?8 PAromatase Inhibitors  Advanced Disease ) ) )H \ 0޽h ? 333380___PPT10.@>^=  0 L0 5 c[  (   [  TFxaxa?R }Postmenopausal women with advanced breast cancer whose disease had progressed/recurred following previous endocrine treatment ~ ~hh88   TFgֳgֳ?\qC -randomized 1:1 (double-blind, parallel-group) . .hh88   Fxaxad @1?U  *anastrozole 1mg daily orally (n=194) N=2298+  $hh88v2  NG) @1?p L2   `-G)d @1?@`2  Z;G)y @1?/V   DFxaxaLd @1?u  B fulvestrant 250mg (2 x 2.5ml) i.m. once monthly (n=206) (N=222)8C 44 -hh88  T4Fgֳgֳ?x b( 2hh88   `(Fgֳgֳ ?  F   Z0Fgֳgֳ?" 7 `   ZFgֳgֳ?"  ` k  TdFgֳgֳ? %Osborne CK et al. JCO 2002; 20: 3386 & &`\   `Яgֳgֳ?| P  Howell A et al. JCO 2002;20:3396 ! !Jhh88H  0޽h ? Oa(<  0 L0 5 u<m<<<( <(  (  (  `gֳgֳ?`k \ hh88 (  `gֳgֳ?` ^ hh88 (  `0gֳgֳ?`k ` 2hh88 (  `0gֳgֳ?` ` 2hh88 (  `<0gֳgֳ ?   h (  `0gֳgֳ? ^Hazard ratio (95% CI): 0.92 (0.74 1.14); p=0.4360 ) 4hh883L 2> ( # lB  (  <8c?,-# XT +,$   ( # ,$ lB  (  <1?+# ,$ lB  (  <1?+2 ,3 lB  (  <1?+F ,G lB (  <1?+T ,U lB (  <1?+b ,c lB (  <1?+u,vlB (  <1?+,lB (  <1?+,lB (  <1?+,lB (  <1?+,lB (  <1?+,lB (  <8c?(# '$ T ,/ '3  ( # ,/ '[ lB ( <1?,/ ,3 lB ( <1?/ 3 lB ( <1?* / * 3 lB ( <1? / 3 lB ( <1?)/ )3 lB ( <1?/ 3 lB ( <1?'/ '3  (   `Bx CDEF8c?DD N NSS.c.c\h\hhrr}}&&TT__kk  44ccn##((( - -8383O3Z=Z=f=qBqB}G}GRRRWWgg  $$//;;FFRR]]AAAFFKKKPPVV-j-j8jDpDpOOffrr}}  @@Zddiinnnyy $66AAMMXXddoIoIhhww}}    ""-"-3\3\??PPP'P'[;[[[[[~~Ei$$Nww# # 67 67 M= M= dW d d d 5 w w @,x    (   B C DEF8c?DD S SXX#h#h?m?mKrKrVrxx  Nkkvv    //WWbnn##C(C((--33#3/=/=;=]B]BnGnGzGRRR\\ggqq""''66'K'KOVOVZ`Z`fefe}j}j    %%0??EEYYdd/n/n;y;yG~G~RR^oozz..>>XX     ''333DDOOr''jj  6X6m66XXuu- - < j j     @,  !(  Z\0?R i  ]0.0   "(  Z\0?R x  ]0.1   #(  Z\0?R   ]0.2   $(  Z0?R   ]0.3   %(  Z0?R"   ]0.4   &(  Z0?R5 ]0.5   '(  Z0?RC ]0.6   ((  Z0?RR ]0.7   )(  Z0?R` ]0.8   *(  Z0?Rt ]0.9   +(  Z?R ]1.0   ,(  Z?z ] [0   -(  Z?z  [6   .(  ZP? z u  \12   /(  ZLJ?w z  \18   0(  ZDX?z s \24   1(  Z``?tz  \30   2(  Zj?z q \36   3(  Z4|? vTime to progression (months)    4(   `?2  sProportion not progressed   5(  T8gֳgֳ? a> PMedian TTP: fulvestrant 5.4 months (n=206) Anastrozole 3.4 months (n=194)RQ (! 7 4hh88l 6(  <1?&lB 7(  <8c?x 8(  Z?B fulvestrant 250mg  lB 9(  <8c?x :(  ZPR?^ gAnastrozole 1mg  ;( Zgֳgֳ?"  ` = <( Tgֳgֳ? #Osborne CK et al. JCO 2002;20:3386 $ $4H ( 0޽h ? Oa(?E  0 L0 5 DDpGGT SD(  T  T T`Hgֳgֳ?U b( 2hh88 T T(Hgֳgֳ?L  JMedian TTP: fulvestrant 5.5 months (n=222) Anastrozole 5.1 months (n=229)RK $ 4 hh88h T  ``Hgֳgֳ? ^Hazard ratio (95% CI): 0.98 (0.80 1.21); p=0.8460 ) 4hh88 T  `|,Hgֳgֳ ?  H  T Tp4Hgֳgֳ?&F ` W T Z6Hgֳgֳ?h !Howell A et al. JCO 2002; 20:3396 " "Jhh88=L *j T # jlB  T  <8c?,, lB  T  <8c?- / T +,.   T # ,. lB  T  <1?+ , lB  T  <1?+2 ,2 lB T  <1?+> ,> lB T  <1?+Q ,Q lB T  <1?+\ ,\ lB T  <1?+p,plB T  <1?+,lB T  <1?+,lB T  <1?+,lB T  <1?+,lB T  <1?+,lB T  <1?,. ,.  T   xB CDEF8c?FFiipp-w-wE~E~MMc9&9&H3H3P3_C_CgJgJWWWtttzz-[[zz1GGffu}}###00GGG$a$a,,<<JJZZbbrrxx''... 4 4BB/Q/Q7_7_??OOVVeemm|#|#EELL[[bbw  $&$&,I,I;Q;QC^C^RRZ?Z?i[i[qbqbiii  II       ///"/"????]p]]ll||  4 4             M M a a ;~ ;~ Q Q o o. oB oB   @,  T   B CDEF8c?bbvv-55TTkks  19 9 P&P&g&},},333;;CCCPPWWW^^fffll%t%tLzLz88mm,,<<JJRRbSbSqZqZaa---44;; B B!I!I7P7P?PGXGXVlVlmsmstztz||**EELL S S$$,,33JJYaaxx  PP^^ll>>EEbivv~ 66FFFF-F-NlNsNs\\ll||7MMZbb ] ] t {        # # ;v ;~ ; ; I I IO I I I I7 Ih I I I I I @,%  T  ZFHgֳgֳ? !  ]0.0  hh88 T  ZPHgֳgֳ? !  ]0.1  hh88 T  ZZHgֳgֳ? !  ]0.2  hh88 T  ZcHgֳgֳ? !  ]0.3  hh88 T  ZttHgֳgֳ? !  ]0.4  hh88 T  Z@vHgֳgֳ?! ]0.5  hh88  T  Z@Hgֳgֳ?+! ]0.6  hh88 !T  Z@Hgֳgֳ?7! ]0.7  hh88 "T  Z@Hgֳgֳ?I!  ]0.8  hh88 #T  Z@Hgֳgֳ?W! ]0.9  hh88 $T  ZHgֳgֳ?j!* ]1.0  hh88 %T  ZHgֳgֳ?4 y  [0  hh88 &T  ZHgֳgֳ?4   [2  hh88 'T  Z Hgֳgֳ?4   [4  hh88 (T  Z Hgֳgֳ?:4   [6  hh88 )T  Z Hgֳgֳ?k 4   [8  hh88 *T  ZHgֳgֳ?n 4 _  \10  hh88 +T  ZxHgֳgֳ? 4  \12  hh88 ,T  ZxHgֳgֳ? 4  \14  hh88 -T  Z8gֳgֳ? 4   \16  hh88 .T  ZHgֳgֳ? 4   \18  hh88 /T  Z8gֳgֳ?94 *  \20  hh88 0T  ZP8gֳgֳ?`4 Q  \22  hh88 1T  ZP"8gֳgֳ?4 x  \24  hh88 2T  ZP,8gֳgֳ?4   \26  hh88 3T  Zp>8gֳgֳ?u  vTime to progression (months)  hh88 4T   ``H8gֳgֳ?*  xProportion without progression  hh88l 5T  <1?`lB 6T  <8c?= 7T  ZK8?x fulvestrant 250mg  lB 8T  <8c?=|} 9T  ZZ8?. gAnastrozole 1mg rB :T  BD?* *? rB ;T  BD? ? rB T  BD? ? rB ?T  BD?c c? rB @T  BD?@ @ ? rB AT  BD?  ? rB BT  BD? ? rB CT  BD? ? rB DT  BD? ? rB ET  BD?t t? rB FT  BD?J J? rB GT  BD?- -? H T 0޽h ? Oa(<  0 L0  $(   r  S $c8  8 r  S c8Pp 8 H  0޽h ? f3380___PPT10.l   0 L0 5  (      ` țgֳgֳ ?      `gֳgֳ ?Pp  H  0޽h ? f33y___PPT10Y+D=' a= @B +< 0 L0  $(   r  S @i8> 8 r  S j8 `   8 H  0޽h ? f3380___PPT10.3`4N 0   (   d   c $qr      s *pe ?3   FDisease-free survival was significantly greater in the anastrozole group compared with the tamoxifen group, with a 13% lesser risk of recurrence and an absolute difference of 2.9% between treatment arms. The divergence in curves which begins at 1 year continues and increases out to 6 years, i.e. after treatment completion. This  carry-over effect appears greater in the anastrozole group than in the tamoxifen group.` H   0whg ? ̙33 0  d(  d  c $qr     s *e ?3   NThere was no significant difference in overall survival between groups, although the data need more time to mature before survival differences can become apparent. However, at this stage, anastrozole demonstrates non-inferiority to tamoxifen, i.e it is at least as effective. There are slightly more non-breast cancer deaths in the anastrozole group (176 vs 155 in the tamoxifen group) and fewer breast cancer deaths in the anastrozole group (235 vs 265 in the tamoxifen group), which may have diluted the effect.  ` H  0whg ? ̙33\ 0  Xl(  Xd X c $po    X s *\<e @1   V*What Tony has just explained is one very interesting perspective: TAM vs ANA. I d like to tell you about a different one: the importance of switchingy       H X 0whg ? ̙3380___PPT10.  0 |t d (  dd d c $po   h d s * e @1   The results were generated from a combined analysis of 3,224 patients who received - either 3 years of TAM - or 3 years of ANA after primary surgery and exposure to 2 years of TAM.                                       H d 0whg ? ̙3380___PPT10.Җ~# 0  ps(  pd p c $po    p s * e @1   ]This Kaplan Meier plot of EFS demonstrates the highly significant benefit for our patients switching to ANA after 2 years of TAM over those remaining on TAM. The HR was 0.59 ......... A truely impressive outcome !8                                         H p 0whg ? ̙33 0 $ (  $ D $  ` 5 D[ D[  ?o @F   *Postmenopausal women with artificially or naturally induced menopause, whose disease had progressed following endocrine therapy, were randomized to receive monthly injections of ICI 182,780 or daily anastrozole tablets The design was double-blind, double-dummy The primary endpoint was time to progression (TTP) Secondary endpoints included: objective response (OR) duration of response (DoR) tolerability Initially, patients were also randomized to a third arm of ICI 182,780 125mg but a preliminary data summary showed insufficient evidence of activity6V@V@ocBBSS $  T1 ?Bvh7   H $ 0whg ? a(> 0 , (  ,  ,  `: D[ D[  ?o @F   No statistically significant difference was seen between treatment groups in terms of TTP ICI 182,780 is at least as effective as anastrozole in the second-line treatment of postmenopausal women with advanced breast cancerocBBSS ,  T1 ?Bvh7   H , 0whg ? a(> 0 X (  X  X  `S D[ D[  ?o @F   No statistically significant difference was seen between treatment groups in terms of TTP ICI 182,780 is at least as effective as anastrozole in the second-line treatment of postmenopausal women with advanced breast cancerocBBSS X  T1 ?Bvh7   H X 0whg ? a(  0 < T(  <  <  `1 ?qm   t <  `dZ r|r| ?e ?1   ZOL =  Zoladex 3.6mg TAM = tamoxifen CMF = cyclophosphamide + methotrexate + 5-fluorouracilH < 0whg ? ̙33<  0 0D (  D  D  `1 ?qm    D  `>==--r--$>??>>--s--$?@@??--t--$@AA@@--u--$ABBAA--v--$BCCBB--x--$CDDCC--y--$DEEDD--{--$EFFEE--|--$FGGFF--}--$GHHGG--~--$HIIHH----$IJJII----$JKKJJ----$KLLKK----$LMMLL----$MOOMM----$OPPOO----$PQQPP----$QRRQQ----$RSSRR----$STTSS----$TUUTT----$UWWUU----$WYYWW----$YZZYY----$Z\\ZZ----$\^^\\----$^``^^----$`bb``----$bddbb----$dhhdd----$hkkhh----$kookk----$ouuoo----$uxxuu---'@"Arial-. -2 -!ADVANCES IN THE HORMONAL o."Systemg-@"Arial-. .2 4TREATMENT OF BREAST CANCER.-@"Arial-. 2 H+TURKISH.-@"Arial-.  2 H>-.-@"Arial-. $2 H?HELENIC ESMO COURSE.-@"Arial-.  2 O.1.-@"Arial-.  2 O0-.-@"Arial-. 2 O14 DECEMBER 2005.-@"Arial-.  2 OZ-.-@"Arial-. 2 O\ iSTANBUL .-@"Arial-.  2 UFP.-@"Arial-.  2 UIi.-@"Arial-. 2 UJ nar Saip .-@"Arial-. 2 [#University of .-@"Arial-.  2 [>I.-@"Arial-. 62 [@stanbul, Institute of Oncology .-@"Arial-. 42 `.Department of Medical Oncology.-՜.+,0L     On-screen Show AstraZenecaW8; CTimes New RomanArial WingdingsTahoma Gill Sans MTSymbol Arial BlackDefault Design4ADVANCES IN THE HORMONAL TREATMENT OF BREAST CANCER4Advances in the Hormonal Treatment of Breast Cancer2Proper selection of endocrine responsive disease 0HR positive disease is heterogeneous disease1HR positive disease is heterogeneous disease 5There is an inverse relationship between PR and HER2"Relationship between ER and HER 2%Prediction of response to tamoxifen uA Multigene assay to predict recurrence of tamoxifene treated, nod (-) breast cancer Paik et al NEJM 2004;351: 2817Multivariate Cox analysisPaik et al ASCO 2005!ST GALLEN CONSENSUS MEETING 20052005 St Gallen 5FEATURES OF UNCERTAINITY TO ENDOCRINE RESPONSIVENESS* ADVANCES IN ADJUVANT ENDOCRINE THERAPY Systemic adjuvant endocrine treatment for early breast cancer significantly reduces recurrence and mortality 15 years after treatment(EBCTCG) meta-analysis Reduction after 15 years HOvarian supression/ablation Alone as an Alternative to Chemotherapy: "OA/OS alone vs Chemotherapy (CMF) "OA/OS + Tamoxifen vs chemotherapy<Ovarian ablation/supression + Tamoxifen vs chemotherapy (1) +Chemotherapy vs CT OA TAM6 Ovarian ablation/supression after chemotherapy (2) Conclusions Questions in the onging trials%Endocrine responsive St Gallen 2005 .Endocrine response uncertain St Gallen 2005 DAdvances in the adjuvant hormonal treatment of postmenapausal womenKResults of the ATAC trial after 5 years adjuvant treatment -Upfront AI ) Disease-free survival (ITT* population)"Overall survival (ITT population)Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,224 women enrolled in the ABCSG Trial 8 and the ARNO 95 trialESwitching trial ABCSG 8 ARNO 95: Combined analysis trial structureEvent-free survivalpIntergroup exemestane study-IES: 50% nod-, 80%HR+, n:4742 median follow up 30.6 months swithcing trial ;Intergroup exemestane study 0Extended AI trial letrozol vs placebo -MA 179MA.17 Results: Disease-Free Survival (Primary End Point) MA.17 Results: Overall Survival+MA.17 Results: Subanalysis of Nodal StatusBBest ajuvant endocrine treatment strategy in postmenapausal womenUnanswered QuestionsOngoing trials ASCO Technology assessment on the use of AIs as adjuvant therapy for postmenapausal women with HR+ breast cancer: Status report 2004 Advances Neoadjuvant phase III trialsP024:Response rates and HER #Advances in the hormonal treatmentkLHRH Agonist + Tamoxifen in Pre-/perimenopausal Women with Advanced Breast Cancer: An EORTC Meta-analysis Slide 53`Fulvestrant vs anastrozole after first line TAM US and rest , Randomized, Double-blind 2 trials/Fulvestrant vs anastrozole Time to Progression/Fulvestrant vs anastrozole Time to ProgressionFulvestrant vs TAM first line 9Endocrine therapy in Advanced Breast Cancer: Conclusions Thank you  Fonts UsedDesign Template Slide Titles;"_3 0Sefik ONATSefik ONAT  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstvwxyz{|}~Root EntrydO)PicturesCurrent UserSummaryInformation(uT,PowerPoint Document(WDocumentSummaryInformation8Root EntrydO)P D @PicturesCurrent User/SummaryInformation(uT,_3TolgaTolga